BioCentury | Jul 15, 2020
Product Development

Repurposing hopes for Tavalisse in COVID-19 breathe life into Rigel shares

...million, after it said on Tuesday Imperial College London will evaluate the efficacy of Tavalisse fostamatinib...
...Institute of MIT and Harvard researchers screened to identify FDA-approved compounds that reduce MUC1 abundance, Tavalisse...
...Mucin 1 SYK - Spleen tyrosine kinase Jeff Cranmer, Executive Editor Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Rigel...
BioCentury | Nov 16, 2019
Company News

Novartis gains CHMP support in MS, Cushing syndrome

...fostamatinib from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for primary immune thrombocytopenia. Jonathan Block, Associate Editor Mayzent, siponimod (BAF312) Tavalisse, fostamatinib...
...Inc. (NASDAQ:RIGL) for primary immune thrombocytopenia. Jonathan Block, Associate Editor Mayzent, siponimod (BAF312) Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Novartis...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...spleen tyrosine kinase (SYK) inhibitor Tavalisse fostamatinib in adults with ITP ( No. 736 ). Tavalisse...
BioCentury | Nov 2, 2018
Company News

Rigel grants Kissei Asian rights to Tavalisse

...Rigel granted Kissei exclusive rights to develop and commercialize Tavalisse fostamatinib for all current and future...
...front and is eligible for $147 million in development and commercial milestones. Rigel will supply Tavalisse...
...Calif. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Business: Autoimmune Shannon Lehnbeuter Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Kissei...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...to a resubmitted BLA for Andexxa andexanet alfa Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) FDA approves Tavalisse fostamatinib...
BioCentury | Apr 27, 2018
Financial News

Rigel raises $62.4M in follow-on

...were off $0.22 to $3.84 on April 20. On April 17, FDA approved Rigel's Tavalisse fostamatinib...
...approved product (see BioCentury, April 20) . Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Paul Bonanos fostamatinib Tavalisse Rigel...
BioCentury | Apr 20, 2018
Clinical News

Rigel gets first FDA approval with Tavalisse

...FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic...
...be approved by any regulatory agency since its founding in 1996. Rigel expects to launch Tavalisse...
...Francisco, Calif. Business: Autoimmune Product: Tavalisse fostamatinib (formerly R788, tamatinib fosdium) Allison Johnson Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Rigel...
BioCentury | Apr 20, 2018
Financial News

Days after first drug approval, Rigel raises $62.4M

...Its shares were off $0.22 to $3.84 on Friday. On Tuesday, FDA approved Rigel's Tavalisse fostamatinib...
BioCentury | Apr 17, 2018
Company News

Rigel clinches its first approval with ITP drug

...FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic...
...be approved by any regulatory agency since its founding in 1996. Rigel expects to launch Tavalisse...
...was up a further $0.32 to $4.55 in after-hours trading. Allison Johnson Tavalisse, fostamatinib (r788, tamatinib fosdium, FosD, R406) Rigel...
Items per page:
1 - 10 of 167